| Day 1 – Thursday, October 22, 2026 | |
|---|---|
| 17:00-17:15 | Welcome note |
| 17:15-18:00 | Plenary lecture: Future perspective in CAR T therapy in Autoimmunity Huji Xu, Beijing |
| 18:00-20:00 | Welcome Reception |
| Day 2 – Friday, October 23, 2026 | |
|---|---|
| 09:00-09:10 | Welcome and vision for the congress Ricardo Grieshaber-Bouyer, Dror Mevorach and Arnon Nagler |
| 09:10-11:10 | Session 1: CAR T in autoimmunity: Present and Future Chairs: TBA |
| 09:10-09:40 | History of CAR T cell therapy Michel Sadelain, New York |
| 09:40-10:10 | Advanced CAR T: In Vivo CAR T TBA |
| 10:10-10:40 | Next generation CAR T cell therapy for autoimmunity and cancer Michael Schmitt, Heidelberg |
| 10:40-11:10 | Antigen-specific CAR T cell therapy Christoph Ellebrecht, Philadelphia |
| 11:10-11:30 | Coffee break |
| 11:30-13:00 | Session 2: Bispecific in autoimmunity: Present and Future Chairs: TBA & Ricardo Grieshaber-Bouyer |
| 11:30-12:00 | The history of bispecific antibodies in autoimmunity TBA |
| 12:00-12:30 | New applications for autoimmunity of bispecific and trispecific antibodies Patrick Baeuerle, Cambridge |
| 12:30-13:00 | CAR T and bispecific comparative safety in autoimmune diseases Henrik Schulze-Koops, Munich |
| 13:00-13:45 | Lunch |
| 13:45-15:15 | Session 3: From haemato-oncology to autoimmunity Chairs: TBA & Arnon Nagler |
| 13:45-14:15 | Clinical experience applying CAR T cells in rheumatic diseases TBA |
| 14:15-14:45 | Current European guidelines for HSCT and CAR T in autoimmune diseases TBA |
| 14:45-15:15 | 20 years of CAR T cells TBA |
| 15:15-15:40 | Coffee break |
| 15:40-17:10 | Session 4: What have we learned from B cell targeting about pathophysiology of autoimmunity Chairs: Dror Mevorach & Danae Noethling |
| 15:40-16:10 | SLE revisited William Robinson, Stanford |
| 16:10-16:40 | Scleroderma revisited TBA |
| 16:40-17:10 | B cell targeting in nephrological diseases TBA |
| 17:10-18:00 | Session 5: Debate Chairs: TBA |
| 17:10-18:00 | Autologous Vs. Heterologous CAR T Arnon Nagler, Ramat Gan & Raffaella Greco, Milano |
| Day 3 – Saturday, October 24, 2026 | |
|---|---|
| 09:00-11:00 | Session 6: Near future perspectives I Chairs: Arnon Nagler & TBA |
| 09:00-09:30 | Comparison between CAR-BCMA and CAR CD19 in autoimmunity TBA |
| 09:30-10:00 | Allogeneic versus autologous CAR T TBA |
| 10:00-10:30 | Academic CAR T, commercial CAR-T or both? TBA |
| 10:30-11:00 | Restoring tolerance beyond CAR-T Dror Mevorach, Jerusalem |
| 11:00-11:20 | Coffee break |
| 11:20-14:00 | Session 7: 5 years of CAR-T- and T-cell engagers in autoimmunity Chairs: TBA |
| 11:20-11:50 | SLE: How do you choose the right patient for Cellular and Humoral Therapy? Thomas Dörner, Berlin |
| 11:50-12:20 | Rheumatoid arthritis: How do you choose the right patient for Cellular and Humoral Therapy? Gerhard Krönke, Berlin |
| 12:20-12:50 | Scleroderma: How do you choose the right patient for Cellular and Humoral Therapy? Hanns-Martin Lorenz, Heidelberg |
| 12:50-13:20 | Myositis: How do you choose the right patient for Cellular and Humoral Therapy? TBA |
| 13:20-13:50 | B cell targeting in autoimmune liver diseases Richard Taubert, Hannover |
| 13:50-14:00 | A panel discussion: What is the role today for Cellular and Humoral Therapy in autoimmunity |
| 14:00-14:45 | Lunch |
| 14:45-15:45 | Session 8: Near future perspectives II Chairs: Gerhard Krönke & William Robinson |
| 14:45-15:15 | Next generation precision cell depletion for autoimmune diseases TBA |
| 15:15-15:45 | Resetting autoimmunity in immune-mediated inflammatory diseases Ricardo Grieshaber-Bouyer, Erlangen |
| 15:45-16:30 | Session 9: Debates Chairs: Henrik Schulze-Koops |
| 15:45-16:30 | CAR T or BiTE for autoimmunity? William Robinson, Stanford & TBA |
| 15:45-16:30 | CAR T or BiTE for autoimmunity? TBA & Patrick Baeuerle, Cambridge |
| 16:30 | Closing remarks Dror Mevorach, Arnon Nagler and Ricardo Grieshaber-Bouyer |
